In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
UroGen Pharma Ltd (NASDAQ: URGN) closed the day trading at $14.96 up 3.10% from the previous closing price of $14.51. In other words, the price has increased by $3.10 from its previous closing price. On the day, 0.87 million shares were traded. URGN stock price reached its highest trading level at $15.77 during the session, while it also had its lowest trading level at $14.02.
Ratios:
For a better understanding of URGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.20 and its Current Ratio is at 7.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 08, 2023, Downgraded its rating to Hold and sets its target price to $10 from $35 previously.
On April 27, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $20.
H.C. Wainwright reiterated its Buy rating for the stock on April 16, 2020, while the target price for the stock was revised from $53 to $57.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 10 ’24 when Schoenberg Mark sold 5,153 shares for $13.08 per share. The transaction valued at 67,401 led to the insider holds 144,284 shares of the business.
Schoenberg Mark sold 12,000 shares of URGN for $168,600 on Mar 18 ’24. The Chief Medical Officer now owns 139,437 shares after completing the transaction at $14.05 per share. On Jan 31 ’24, another insider, Smith Jason Drew, who serves as the General Counsel of the company, sold 4,993 shares for $15.74 each. As a result, the insider received 78,590 and left with 18,824 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 630026944 and an Enterprise Value of 459209056. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.31. Its current Enterprise Value per Revenue stands at 5.447 whereas that against EBITDA is -6.702.
Stock Price History:
Over the past 52 weeks, URGN has reached a high of $24.13, while it has fallen to a 52-week low of $10.60. The 50-Day Moving Average of the stock is -5.05%, while the 200-Day Moving Average is calculated to be 0.60%.
Shares Statistics:
Over the past 3-months, URGN traded about 651.74K shares per day on average, while over the past 10 days, URGN traded about 370820 shares per day. A total of 41.17M shares are outstanding, with a floating share count of 37.26M. Insiders hold about 9.50% of the company’s shares, while institutions hold 78.16% stake in the company. Shares short for URGN as of 1722384000 were 6100670 with a Short Ratio of 9.36, compared to 1719532800 on 6337841. Therefore, it implies a Short% of Shares Outstanding of 6100670 and a Short% of Float of 15.18.
